Pylopass, a digestive-health ingredient made from inactivated Lactobacillus reuteri cells, enters the U.S. market for the first time this month under the Life Extension brand.
Maypro Industries (Purchase, NY) announced this week that Pylopass, a digestive-health ingredient manufactured by German biotechnology company Organobalance, will be making its debut on the U.S. dietary supplements market. The ingredient, for which Maypro is the sole distributor, will be included in the supplement product Gastro-Ease under the Life Extension brand.
Pylopass was developed to combat the harmful stomach bacterium Helicobacter pylori, Maypro explains in the launch announcement, which is a gram-negative, spiral-shaped bacterium that can cause digestive-health issues by secreting enzymes that neutralize stomach acid. Maypro describes Pylopass as “a natural lactic acid bacterium from [Organobalance’s] microorganisms strain collection made from spray-dried inactivated cells of Lactobacillus reuteri,” which has been shown to reduce H. pylori counts. More than two-thirds of the world’s population is infected with H. pylori, Maypro notes, citing a report from the Center for Disease Control and Prevention (CDC).
“Pylopass has a unique effect against this carcinogenic stomach bacterium,” explains Christine Lang, PhD, microbiologist and managing director for Organobalance, in the launch announcement. “Unlike conventional therapies involving antibiotics which can harm the human microbiome, consumers who are taking Pylopass can lower their Helicobacter pylori load without losing their natural bacterial balance in their gut.”
While Pylopass is already on the market in many other countries, Life Extension is the first company to release a product with the ingredient on the U.S. market, Maypro adds. The shelf-stable ingredient is non-GMO and holds self-affirmed Generally Recognized as Safe (GRAS) status.
Nutritional Outlook Magazine